Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Other Operating Expenses (2016 - 2025)

Angiodynamics (ANGO) has disclosed Other Operating Expenses for 16 consecutive years, with $39.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to $39.5 million, compared with a TTM value of $82.8 million through Nov 2025, up 1144.45%, and an annual FY2024 reading of $54.5 million, changed N/A over the prior year.
  • Other Operating Expenses was $39.5 million for Q4 2025 at Angiodynamics, down from $43.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $47.8 million in Q3 2023 and bottomed at $6.7 million in Q1 2024.
  • Average Other Operating Expenses over 5 years is $31.4 million, with a median of $30.7 million recorded in 2021.
  • Peak annual rise in Other Operating Expenses hit 23.8% in 2021, while the deepest fall reached 83.22% in 2021.
  • Year by year, Other Operating Expenses stood at $29.1 million in 2021, then rose by 9.58% to $31.9 million in 2022, then surged by 50.01% to $47.8 million in 2023, then plummeted by 86.09% to $6.7 million in 2024, then surged by 493.44% to $39.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for ANGO at $39.5 million in Q4 2025, $43.3 million in Q3 2025, and $6.7 million in Q1 2024.